Search company, investor...
Antidote company logo


Founded Year



Series D | Alive

Total Raised


Last Raised

$23.2M | 2 yrs ago

About Antidote

Antidote is a digital health company that uses precision recruitment to match the right patients with the right trials. Antidote strikes the right balance between technology and human touch to deliver patient engagement through the integration of data-driven technologies, digital expertise, deep domain experience, a diverse partner network, and personalized patient and site services.

Headquarters Location

39 Earlham Street

London, England, WC2H 9LT,

United Kingdom

+44 20 3475 8201

ESPs containing Antidote

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Life Sciences / Biopharma Tech

Companies in this market raise awareness of clinical trial opportunities and offer software that streamlines patient enrollment into a clinical trial. Solutions leverage varied approaches for finding patients, from AI for electronic health record (EHR) data to building disease-specific patient communities.

Antidote named as Highflier among 15 other companies, including Deep Lens, Elligo Health Research, and TrialJectory.

Compete with Antidote?

Ensure that your company and products are accurately represented on our platform.

Antidote's Products & Differentiators

    Antidote Match

    Trial matching engine that uses structured eligibility criteria (using industry standard and custom-designed ontologies) and proprietary algorithms to explore a patient’s eligibility for every trial

Research containing Antidote

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Antidote in 2 CB Insights research briefs, most recently on Oct 26, 2022.

Expert Collections containing Antidote

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Antidote is included in 4 Expert Collections, including Clinical Trials Tech.


Clinical Trials Tech

341 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.


Digital Health

12,620 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Clinical Trials Tech Market Map

108 items

This CB Insights Tech Market Map highlights 100+ clinical trials tech companies that are addressing 8 distinct technology priorities that pharmaceutical companies and CROs face.


Biopharma Tech

326 items

Antidote Patents

Antidote has filed 3 patents.

The 3 most popular patent topics include:

  • Abandoned drugs
  • Clinical research
  • Clinical trials
patents chart

Application Date

Grant Date


Related Topics



Clinical research, Clinical trials, Design of experiments, Pharmaceutical industry, Clinical data management


Application Date


Grant Date


Related Topics

Clinical research, Clinical trials, Design of experiments, Pharmaceutical industry, Clinical data management



Latest Antidote News

ACC president: ‘Antidote to burnout’ is engagement

Mar 4, 2023

Source: Fry ETA. Disclosures: Fry reports no relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact . Back to Healio NEW ORLEANS — The cardiology community has faced great challenges in recent years, but continuing to engage can help overcome them, American College of Cardiology President Edward T. A. Fry, MD, FACC, FSCAI, said in opening remarks here. “The challenges ahead are many, but as we will see at this meeting and in years to come, the opportunities are boundless,” Fry, who is also chairman of the Ascension Health Cardiovascular Service Line at Ascension Medical Group, Indianapolis, said during his presentation to open the ACC Scientific Session, held in conjunction with the World Heart Federation’s (WHF) World Congress of Cardiology. “There is only one thing that can stand in our way: not engaging [and] not participating in leading the process of transformation. Engagement is the essential characteristic of professionalism and agency. It is the antidote to burnout. Engaging takes effort but reaps tremendous rewards. It is the essential ingredient for success.” “The challenges ahead are many, but as we will see at this meeting and in years to come, the opportunities are boundless,” American College of Cardiology President Edward T. A. Fry, MD, FACC, FSCAI, said. Image: Adobe Stock The state of the fight against CVD after enduring the COVID-19 pandemic “is like a twist on Charles Dickens: It was the worst of times, it was the best of times,” Fry said. “Many challenges facing cardiovascular medicine had their origin before the pandemic, but over the past year, we have seen an accelerated attrition of physicians and care team members as part of the Great Resignation or ‘quiet quitting.’ At the same time, the complexity and prevalence of all forms of heart disease are steadily increasing.” Edward T. A. Fry This has led to the economic failure of many hospitals, and, for the first time in 80 years, a drop in U.S. life expectancy in 2 consecutive years, he said. Although the pandemic and the opioid crisis have contributed to that, it is also driven by “increasing mortality from cardiovascular disease , especially among the poor and minorities, reflecting the disparities of care and the threats to health equity.” Those factors plus bureaucratic barriers to optimizing health care “distract from clinician wellness, and from attracting young people to careers in cardiovascular medicine,” Fry said. “Economic instability and declining support combined with unintended consequences of ineffective regulation have resulted in additional barriers to meeting these goals [of the ACC’s Quadruple Aim] for patients and clinicians in our communities. Increasingly, these challenges ... have led to a sense of futility, compounding clinician wellness and fueling the epidemic of burnout across the team.” A purpose of the meeting, however, is to show how the cardiology community is in the best of times, he said. “ACC and WHF have had to be nimble and creative to meet these sorts of challenges while also moving the fields of cardiovascular medicine and education forward.” Modernization of guidelines, registries, education, publications, advocacy and care delivery have been part of these efforts, Fry said. “One positive that has come out of COVID has been the increase in accessibility of cardiovascular education through an array of in-person and virtual options, making access to current medical knowledge easy, affordable, flexible and customizable,” he said. Another positive development has been more research and publications on maternal CV health, spurred by awareness of the problem of maternal mortality, he said, noting the ACC’s board of trustees has established a clinical section on reproductive health and cardio-obstetrics. An important challenge for the future, Fry said, is “to focus on the efforts upstream to tackle social determinants, public health policy, health care funding and primordial prevention.” To prepare for the future, the ACC “is addressing the composition of our cardiovascular workforce, to ensure that professionals reflect the diversity of the communities we live in and serve in,” Fry said. “We are doing this through initiatives like the ACC Young Scholars Program for high school and college students. In addition, efforts like the new ACC Internal Medicine Residency Program aim to attract residents from diverse backgrounds to pursue careers in cardiology. Leadership development programs also foster equitable opportunity for the underrepresented to lead our profession.” Read more about

Antidote Frequently Asked Questions (FAQ)

  • When was Antidote founded?

    Antidote was founded in 2010.

  • Where is Antidote's headquarters?

    Antidote's headquarters is located at 39 Earlham Street, London.

  • What is Antidote's latest funding round?

    Antidote's latest funding round is Series D.

  • How much did Antidote raise?

    Antidote raised a total of $57.49M.

  • Who are the investors of Antidote?

    Investors of Antidote include Octopus Ventures, Smedvig Capital, Merck Global Health Innovation Fund, LBO France and Amadeus Capital Partners.

  • Who are Antidote's competitors?

    Competitors of Antidote include SubjectWell, Clara Health, TrialJectory, Ancora, TrialSpark and 10 more.

  • What products does Antidote offer?

    Antidote's products include Antidote Match and 4 more.

  • Who are Antidote's customers?

    Customers of Antidote include Merck.

Compare Antidote to Competitors

Trialbee Logo

Trialbee is a dynamic software company with a single purpose of accelerating clinical research. The company provides software solutions that optimize the clinical trial process by enabling all stakeholders to easily communicate and collaborate on a joint platform.


Ancora is a search tool that allows patients to look for relevant clinical trials in an easily searchable, personally tailored way.

Curebase Logo

Curebase runs clinical trials via software that reduces recruitment times, automates manual steps, and lets drug companies distribute their trials to clinics. Curebase was founded in 2017 and is based in San Francisco, California.

Massive Bio Logo
Massive Bio

Massive Bio is an AI powered platform that connects cancer patients and their treating oncologists to clinical trials while enabling pharmaceutical companies to get access to patients, mostly in community practices, and their information to speed up drug development. Massive Bio provides unique tech enabled services and a big data platform that addresses all points of friction in clinical trial enrollment. Massive Bio was founded in 2014 and is based in New York, New York.

Neucruit Logo

Neucruit is a patient recruitment platform for clinical trials that uses real-time data to help biopharmaceutical companies, site teams, and investigators enhance site selection and optimize patient recruitment materials.

Neurish Logo

Neurish is a location-based mobile social network to improve the lives of people affected by epilepsy and other neurological disorders. The company's mission is to connect patients and caregivers to mentors, doctors, events, and other quality resources to improve the quality of life for the patient and caregiver.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.